"The Company notes that, whilst this agreement will not of itself increase revenue, it may indirectly do so by providing the increased network for the provision of MedAdvisor’s programs."
I'm hoping the fees they earn from the pharma companies is much much more than what they could earn just selling/white-labeling the product, but at this stage, it seems MDR shareholders are funding all the development of this product that they are seemingly handing out for free
I hope the new CEO really looks at these arrangements as the cash is running out and they have to be cashflow and ebitda positive soon because further dilution is not looking good
Add to My Watchlist
What is My Watchlist?
